Szilard Kiss - Jun 10, 2024 Form 3 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Director
Signature
/s/ John Rakow, Attorney-in-Fact
Stock symbol
ADVM
Transactions as of
Jun 10, 2024
Transactions value $
$0
Form type
3
Date filed
6/20/2024, 04:42 PM
Next filing
Jun 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ADVM Stock Option (Right to Buy) Jun 10, 2024 Common Stock 1.25K $30.50 Direct F1
holding ADVM Stock Option (Right to Buy) Jun 10, 2024 Common Stock 2K $61.50 Direct F1
holding ADVM Stock Option (Right to Buy) Jun 10, 2024 Common Stock 8K $54.10 Direct F1
holding ADVM Stock Option (Right to Buy) Jun 10, 2024 Common Stock 4.5K $94.50 Direct F1
holding ADVM Stock Option (Right to Buy) Jun 10, 2024 Common Stock 2.5K $14.00 Direct F2
holding ADVM Stock Option (Right to Buy) Jun 10, 2024 Common Stock 2.5K $9.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock option is fully vested and exercisable.
F2 The shares subject to the option vest in equal monthly installments over two years, such that all of the shares subject to the option shall become vested and exercisable as of August 16, 2024, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F3 50% of the shares subject to the option vested on March 25, 2024, and the remainder of the shares subject to the option vest in equal monthly installments thereafter through March 25, 2025, subject to the Reporting Person's continued service with the Issuer on each such vesting date.